Literature DB >> 28414079

In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.

Ryan M Pearson1, Liam M Casey2, Kevin R Hughes1, Stephen D Miller3, Lonnie D Shea4.   

Abstract

Technologies that induce antigen-specific immune tolerance by mimicking naturally occurring mechanisms have the potential to revolutionize the treatment of many immune-mediated pathologies such as autoimmunity, allograft rejection, and allergy. The immune system intrinsically has central and peripheral tolerance pathways for eliminating or modulating antigen-specific responses, which are being exploited through emerging technologies. Antigen-specific tolerogenic responses have been achieved through the functional reprogramming of antigen-presenting cells or lymphocytes. Alternatively, immune privileged sites have been mimicked using biomaterial scaffolds to locally suppress immune responses and promote long-term allograft survival. This review describes natural mechanisms of peripheral tolerance induction and the various technologies being developed to achieve antigen-specific immune tolerance in vivo. As currently approved therapies are non-specific and carry significant associated risks, these therapies offer significant progress towards replacing systemic immune suppression with antigen-specific therapies to curb aberrant immune responses.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allergy; Autoimmune disease; Drug delivery; Immune tolerance; Nanoparticle; Regulatory T cells; Transplantation

Mesh:

Substances:

Year:  2017        PMID: 28414079      PMCID: PMC5582017          DOI: 10.1016/j.addr.2017.04.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  155 in total

Review 1.  Immunological mechanisms of allergen-specific immunotherapy.

Authors:  Mark Larché; Cezmi A Akdis; Rudolf Valenta
Journal:  Nat Rev Immunol       Date:  2006-10       Impact factor: 53.106

2.  Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

Authors:  Daniel R Getts; Danielle M Turley; Cassandra E Smith; Christopher T Harp; Derrick McCarthy; Emma M Feeney; Meghann Teague Getts; Aaron J Martin; Xunrong Luo; Rachael L Terry; Nicholas J C King; Stephen D Miller
Journal:  J Immunol       Date:  2011-08-05       Impact factor: 5.422

3.  B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

Review 4.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 5.  How regulatory T cells work.

Authors:  Dario A A Vignali; Lauren W Collison; Creg J Workman
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

6.  Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.

Authors:  Terese Hylander; Leith Latif; Ulla Petersson-Westin; Lars Olaf Cardell
Journal:  J Allergy Clin Immunol       Date:  2013-02       Impact factor: 10.793

7.  Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis.

Authors:  Joshua O Sestak; Bradley P Sullivan; Sharadvi Thati; Laura Northrup; Brittany Hartwell; Lorena Antunez; M Laird Forrest; Charlotte M Vines; Teruna J Siahaan; Cory Berkland
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-09       Impact factor: 6.698

Review 8.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Baolan Li
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

Review 9.  Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Authors:  C M U Hilkens; J D Isaacs
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

10.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  41 in total

1.  Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model.

Authors:  Qi Liu; Xiang Wang; Xiangsheng Liu; Sanjan Kumar; Grant Gochman; Ying Ji; Yu-Pei Liao; Chong Hyun Chang; Wesley Situ; Jianqin Lu; Jinhong Jiang; Kuo-Ching Mei; Huan Meng; Tian Xia; Andre E Nel
Journal:  ACS Nano       Date:  2019-04-12       Impact factor: 15.881

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Syngeneic red blood cell-induced extracellular vesicles suppress delayed-type hypersensitivity to self-antigens in mice.

Authors:  Katarzyna Nazimek; Eugenio Bustos-Morán; Noelia Blas-Rus; Bernadeta Nowak; Włodzimierz Ptak; Philip W Askenase; Francisco Sánchez-Madrid; Krzysztof Bryniarski
Journal:  Clin Exp Allergy       Date:  2019-08-26       Impact factor: 5.018

4.  Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.

Authors:  Ryan M Pearson; Liam M Casey; Kevin R Hughes; Leon Z Wang; Madeleine G North; Daniel R Getts; Stephen D Miller; Lonnie D Shea
Journal:  Mol Ther       Date:  2017-05-05       Impact factor: 11.454

5.  Conjugation of Transforming Growth Factor Beta to Antigen-Loaded Poly(lactide- co-glycolide) Nanoparticles Enhances Efficiency of Antigen-Specific Tolerance.

Authors:  Liam M Casey; Ryan M Pearson; Kevin R Hughes; Jeffrey M H Liu; Justin A Rose; Madeleine G North; Leon Z Wang; Mei Lei; Stephen D Miller; Lonnie D Shea
Journal:  Bioconjug Chem       Date:  2017-11-30       Impact factor: 4.774

Review 6.  Designing natural and synthetic immune tissues.

Authors:  Emily A Gosselin; Haleigh B Eppler; Jonathan S Bromberg; Christopher M Jewell
Journal:  Nat Mater       Date:  2018-05-21       Impact factor: 43.841

7.  Cargo-less nanoparticles program innate immune cell responses to toll-like receptor activation.

Authors:  Liam M Casey; Sandeep Kakade; Joseph T Decker; Justin A Rose; Kyle Deans; Lonnie D Shea; Ryan M Pearson
Journal:  Biomaterials       Date:  2019-07-04       Impact factor: 12.479

Review 8.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Authors:  Ryan M Pearson; Joseph R Podojil; Lonnie D Shea; Nicholas J C King; Stephen D Miller; Daniel R Getts
Journal:  Nanomedicine       Date:  2018-10-21       Impact factor: 5.307

9.  Localized immune tolerance from FasL-functionalized PLG scaffolds.

Authors:  Michael Skoumal; Kyle B Woodward; Hong Zhao; Feng Wang; Esma S Yolcu; Ryan M Pearson; Kevin R Hughes; Andrés J García; Lonnie D Shea; Haval Shirwan
Journal:  Biomaterials       Date:  2018-11-13       Impact factor: 12.479

Review 10.  Improving Vaccine and Immunotherapy Design Using Biomaterials.

Authors:  Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.